|
1）Roger VL. Epidemiology of heart failure. Circ Res. 2003; 113: 646-59
|
|
|
|
2）Llloyd-Jones D, Adams R, Brown T, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2009; 121: e46-215
|
|
|
|
|
|
3）Yerevanian A, Yerevanian A, Hajjar RJ. Progress in gene therapy for heart failure. J Cardiovasc Pharmacol. 2014; 63: 95-106
|
|
|
|
|
4）Nagai T, Komuro I. Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function. Am J Physiol Heart Circ Physiol. 2012; 303: H501-12
|
|
|
|
|
|
5）Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res. 2015; 108: 4-20
|
|
|
|
|
|
6）Greenberg B. Gene therapy for heart failure. J Cardiol. 2015; 66: 195-200
|
|
|
|
|
7）Laakkonen JP, Yla-Herttuala S. Recent advancements in cardiovascular gene therapy and vascular biology. Human Gene Ther. 2015; 26: 518-24
|
|
|
|
|
|
8）Fish KM, Ishikawa K. Advances in gene therapy for heart failure. Discov Med. 2015; 105: 285-91
|
|
|
|
|
|
9）Horowitz JD, Rosenson RS, McMurray J JV, et al. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther. 2011; 25: 69-76
|
|
|
|
|
|
10）Hayward C, Patel H, Lyon A. Gene therapy in heart failure. SERCA2a as a therapuetic target. Circ J. 2014; 78: 2577-87
|
|
|
|
|
11）Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fial. 2008; 14: 355-67
|
|
|
|
|
|
12）Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 Clinical Trial. J Cardiac Fail. 2009; 15: 171-81
|
|
|
|
|
|
13）Jussup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID). Circulation. 2011; 124: 304-13
|
|
|
|
|
|
14）Greenberg B, Yaroshinsky A, Zsebo KM, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure. JACC Heart Fail. 2014; 2: 84-92
|
|
|
|
|